Plain language summary of the PERSEUS study on daratumumab combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma
This Plain Language Summary of publication article (PLSP) from Future Oncology study looked at adults with newly diagnosed multiple myeloma. Researchers tested if adding daratumumab (D) to the standard treatment of bortezomib (V), lenalidomide (R), and dexamethasone (d) could improve outcomes. Participants were split into two groups: one received D-VRd and daratumumab with lenalidomide during maintenance, while the other received VRd and lenalidomide alone. All participants were eligible for a stem cell transplant.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma’ and was published in The New England Journal of Medicine.
Visit NEJM using the link to read the original article.